FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18 | -55.0% | 8,314 | 0.0% | 0.00% | – |
Q2 2023 | $40 | -39.4% | 8,314 | -28.5% | 0.00% | -100.0% |
Q1 2023 | $66 | -51.1% | 11,634 | -13.0% | 0.00% | 0.0% |
Q4 2022 | $135 | -100.0% | 13,378 | 0.0% | 0.00% | -66.7% |
Q3 2022 | $300,000 | -8.0% | 13,378 | +1.6% | 0.00% | 0.0% |
Q2 2022 | $326,000 | -36.7% | 13,163 | -0.9% | 0.00% | -25.0% |
Q1 2022 | $515,000 | -69.2% | 13,286 | -53.5% | 0.00% | -33.3% |
Q4 2021 | $1,672,000 | +95.3% | 28,568 | +97.9% | 0.01% | -14.3% |
Q3 2021 | $856,000 | -34.9% | 14,436 | -4.7% | 0.01% | -36.4% |
Q2 2021 | $1,314,000 | +47.0% | 15,141 | +39.7% | 0.01% | -67.6% |
Q1 2021 | $894,000 | -12.2% | 10,841 | -3.2% | 0.03% | -12.8% |
Q4 2020 | $1,018,000 | +128.8% | 11,195 | +0.5% | 0.04% | +105.3% |
Q3 2020 | $445,000 | +29.4% | 11,141 | +11.1% | 0.02% | +18.8% |
Q2 2020 | $344,000 | +41.0% | 10,025 | -8.7% | 0.02% | +166.7% |
Q1 2020 | $244,000 | +7.0% | 10,985 | -5.7% | 0.01% | +50.0% |
Q4 2019 | $228,000 | – | 11,653 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |